M. D. Anderson Cancer Center researchers to present CTCE-9908 data at the AACR annual meeting



    TSX: CTI
    OTCBB: CHKT

    VANCOUVER, April 2 /CNW/ - Chemokine Therapeutics Corp. (the "Company")
(TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based
therapies to treat cancer, blood disorders, and vascular diseases, today
announced that the University of Texas M. D. Anderson Cancer Center's
abstract, "Inhibition of primary growth and distant metastasis with a CXCR4
antagonist in a mouse model of breast cancer" authored by Eugene H. Huang,
Balraj Singh, Laura Vincent, Massimo Cristofanilli, Kailash Mosalpuria,
Caimiao Wei, and Anthony Lucci, has been accepted by the American Association
for Cancer Research ("AACR") for oral presentation at its 2007 Annual Meeting
being held in Los Angeles, California. The presentation will be given by
Dr. Eugene Huang on Wednesday, April 18, 2007, as part of the Experimental
Therapeutics Mini-symposium.
    The Meeting is expected to attract more than 15,000 participants from 60
countries to discuss and hear presentations on new and significant discoveries
in basic, clinical, and translational cancer research. The AACR hopes to
identify the most compelling science and ensure that the latest advances in
all areas of cancer research and specifically the most important emerging
research fields are fully covered.
    Researchers at the M. D. Anderson Cancer Center have been studying the
ability of CTCE-9908 to inhibit the metastasis of a human breast cancer in
preclinical models as part of a collaborative research effort with the
Company.

    About CTCE-9908
    CTCE-9908 is a peptide analog of the Chemokine SDF-1, and an antagonist
of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine
that binds to CXCR4, which is present on cancer cells of over 30 different
tumor types. Activation by SDF-1 is believed to be critical in angiogenesis
and in the metastasis (or spread) of cancer cells to distant locations in the
body, where they form new tumors. Approximately 90% of cancer deaths are due
to metastasis. We believe that CTCE-9908 interferes with the metastatic
process of cancers by both preventing their spread and blocking the blood
supply to the cancer cells.
    The Company is currently conducting a Phase Ib/II clinical trial on
CTCE-9908 to assess safety and preliminary efficacy in late stage cancer
patients. Preliminary results were recently released where no dose limiting
toxicities were observed in any of the cancer patients and two out of three
patients with ovarian cancer responded positively and exhibited stable disease
when comparing the size of target tumors at baseline to the assessment
performed after CTCE-9908 treatment. The remaining patients are currently
being enrolled with the final results expected later this year.

    About American Association for Cancer Research
    AACR is one of the oldest and largest scientific organization in the
world focused on every aspect of high-quality, innovative cancer research. Its
reputation for scientific breadth and excellence attract the premier
researchers in the field. The programs and services of AACR foster the
exchange of knowledge and new ideas among scientists dedicated to cancer
research, provide training opportunities for the next generation of cancer
researchers, and increase public understanding of cancer.

    About The University of Texas M. D. Anderson Cancer Center
    M. D. Anderson Cancer Center, a component of The University of Texas
System, has established an international reputation as one of the world's
preeminent centers for cancer patient care, research, education and prevention
with pioneering approaches and technologies. M. D. Anderson holds the
distinction of being designated by the National Cancer Institute (NCI) as one
of the first three Comprehensive Cancer Centers in the United States. M. D.
Anderson has been named the nation's top cancer hospital by U.S. News & World
Report's "Best Hospitals" survey four out of the past six years.

    About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)
    Chemokine Therapeutics is a product-focused biotechnology company
developing drugs in the field of chemokines. Chemokines are a class of
signaling proteins which play a critical role in the growth, differentiation,
and maturation of cells necessary for fighting infection as well as tissue
repair and regeneration. Chemokines also have an important role in cancer
metastasis and growth. Chemokine Therapeutics is a leader in research in the
field of chemokines and has several products in various stages of development.

    Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: Statements in this document regarding managements' future
expectations, beliefs, goals, plans or prospects constitute forward-looking
statements that involve risks and uncertainties, which may cause actual
results to differ materially from the statements made. For this purpose, any
statements that are contained herein that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects", "projects", and similar expressions are intended to
identify forward-looking statements. You are cautioned that such statements
are subject to a multitude of risks and uncertainties that could cause actual
results, future circumstances, or events to differ materially from those
projected in the forward-looking statements. These risks include, but are not
limited to, those associated with the success of research and development
programs, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, financing capability, the
potential dilutive effects of any financing, reliance on subcontractors and
key personnel and other risks detailed from time-to-time in the Company's
public disclosure documents and other filings with the U.S. Securities and
Exchange Commission and Canadian securities regulatory authorities.
Forward-looking statements are made as of the date hereof, and the Company
disclaims any intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.





For further information:

For further information: Chemokine Therapeutics Corp., Mr. Don Evans,
Director of Public Relations, Phone: (604) 822-0305, or 1-888-822-0305, Fax:
(604) 822-0302, E-mail: devans@chemokine.net, Internet: www.chemokine.net;
Equicom Group, Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext.
233, Fax: (416) 815-0080, E-mail: jlongo@equicomgroup.com

Organization Profile

CHEMOKINE THERAPEUTICS CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890